All In Biotech

Drug Trial Radar · NCT06678659

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

A Phase 1 / 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 310 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

310

Planned (sponsor's estimate)

Start

Nov 21, 2024

Primary completion

Jul 2029

Study completion Jul 2029

Sponsor

Lead sponsor
Recursion Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Nov 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.

Conditions

  • Unresectable
  • Locally Advanced
  • Metastatic Cancers
  • Relapsed/Refractory Lymphomas

Interventions

  • REC-1245Drug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1-Part 1A (Dose Finding)- Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Initiation of study drug through 4 weeks
  2. Phase 1 and 2 - Number of Participants With a Treatment-emergent Adverse EventTime frame: Initiation of study drug through 30 days after the last dose (up to approximately 24 months)
  3. Phase 2- Objective Response Rate (ORR)Time frame: Initiation from study drug until disease progression (up to approximately 24 months)

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • Stanford Women's Cancer Center

    Palo Alto, California · Recruiting

  • Sarcoma Oncology Research Center

    Santa Monica, California · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • SCRI Oncology Partners - PPDS

    Nashville, Tennessee · Withdrawn

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • McGill University Health Centre (MUHC) - The Montreal

    Québec, Canada · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.